Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Genes (Basel) ; 13(1)2022 01 13.
Article in English | MEDLINE | ID: mdl-35052478

ABSTRACT

The Wnt pathway is involved in several processes essential for bone development and homeostasis. For proper functioning, the Wnt pathway is tightly regulated by numerous extracellular elements that act by both activating and inhibiting the pathway at different moments. This review aims to describe, summarize and update the findings regarding the extracellular modulators of the Wnt pathway, including co-receptors, ligands and inhibitors, in relation to bone homeostasis, with an emphasis on the animal models generated, the diseases associated with each gene and the bone processes in which each member is involved. The precise knowledge of all these elements will help us to identify possible targets that can be used as a therapeutic target for the treatment of bone diseases such as osteoporosis.


Subject(s)
Bone Diseases/pathology , Bone and Bones/physiology , Homeostasis , Osteogenesis , Wnt Signaling Pathway , Animals , Bone Diseases/metabolism , Bone and Bones/metabolism , Humans
2.
Int J Mol Sci ; 22(14)2021 Jul 09.
Article in English | MEDLINE | ID: mdl-34299011

ABSTRACT

Osteoporosis is the most common metabolic bone disorder and nitrogen-containing bisphosphonates (BP) are a first line treatment for it. Yet, atypical femoral fractures (AFF), a rare adverse effect, may appear after prolonged BP administration. Given the low incidence of AFF, an underlying genetic cause that increases the susceptibility to these fractures is suspected. Previous studies uncovered rare CYP1A1 mutations in osteoporosis patients who suffered AFF after long-term BP treatment. CYP1A1 is involved in drug metabolism and steroid catabolism, making it an interesting candidate. However, a functional validation for the AFF-associated CYP1A1 mutations was lacking. Here we tested the enzymatic activity of four such CYP1A1 variants, by transfecting them into Saos-2 cells. We also tested the effect of commonly used BPs on the enzymatic activity of the CYP1A1 forms. We demonstrated that the p.Arg98Trp and p.Arg136His CYP1A1 variants have a significant negative effect on enzymatic activity. Moreover, all the BP treatments decreased CYP1A1 activity, although no specific interaction with CYP1A1 variants was found. Our results provide functional support to the hypothesis that an additive effect between CYP1A1 heterozygous mutations p.Arg98Trp and p.Arg136His, other rare mutations and long-term BP exposure might generate susceptibility to AFF.


Subject(s)
Cytochrome P-450 CYP1A1/genetics , Cytochrome P-450 CYP1A1/metabolism , Femoral Fractures/genetics , Femoral Fractures/metabolism , Amino Acid Sequence , Cell Line , Cell Line, Tumor , Cell Survival/genetics , Cytochrome P-450 CYP1A1/chemistry , Diphosphonates/therapeutic use , Femoral Fractures/enzymology , Humans , Incidence , Mutagenesis, Site-Directed , Mutation, Missense , Phylogeny , Sequence Alignment
SELECTION OF CITATIONS
SEARCH DETAIL
...